GLP1R and type 2 diabetes mellitus: Given the evidence showing that GLP-1 receptors are expressed, to a lesser extent, in muscle tissues, further GLP-1 receptor signaling as provided by the GLP-1 receptor agonist administration may be needed to enhance muscle regeneration and increase skeletal muscle mass in T2D patients, and this idea may partly explain why the group treated with a combination of miglitol plus sitagliptin, which caused the highest plasma aGLP-1 excursion among the three treatment groups, failed to increase SMI.